Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hrishi Venkatesh

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Experimental Medicine|August 7, 2025
CD4+ T cell dysfunction in cancerHrishi Venkatesh, Lawrence Fong
Frontiers in Immunology|September 1, 2023
Cytotoxic CD4 T cells in the mucosa and in cancerHrishi Venkatesh, Sean I Tracy, Michael A Farrar
Blood|March 11, 2022
Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemiaSean I Tracy, Hrishi Venkatesh, Can Hekim, et al.
NPJ Systems Biology and Applications|June 17, 2022
Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancerAlexander T Wenzel, Devora Champa, Hrishi Venkatesh, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSEElizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centenos, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Leukemia escapes immunity by imposing a Type-1 regulatory program on neoantigen-specific CD4+ T cellsHrishi Venkatesh, Lynn Heltemes-Harris, Miriam Arroyo, et al.
Blood|September 4, 2025
Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cellsHrishi Venkatesh, Enoc Granados Centeno, Qianyun Luo, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Experimental Medicine|August 7, 2025
CD4+ T cell dysfunction in cancerHrishi Venkatesh, Lawrence Fong
Frontiers in Immunology|September 1, 2023
Cytotoxic CD4 T cells in the mucosa and in cancerHrishi Venkatesh, Sean I Tracy, Michael A Farrar
Blood|March 11, 2022
Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemiaSean I Tracy, Hrishi Venkatesh, Can Hekim, et al.
NPJ Systems Biology and Applications|June 17, 2022
Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancerAlexander T Wenzel, Devora Champa, Hrishi Venkatesh, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSEElizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centenos, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Leukemia escapes immunity by imposing a Type-1 regulatory program on neoantigen-specific CD4+ T cellsHrishi Venkatesh, Lynn Heltemes-Harris, Miriam Arroyo, et al.
Blood|September 4, 2025
Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cellsHrishi Venkatesh, Enoc Granados Centeno, Qianyun Luo, et al.
Pageof 1